| Literature DB >> 33966721 |
Abstract
COVID-19 a pandemic disease caused by the SARS-CoV2 virus, which has been emerged in Wuhan city China from early December 2019 which subsequently spreading globally. As a consequence of the physiological adaptive changes and immunosuppressive condition during pregnancy are more susceptible to respiratory tract infection and pneumonia that perhaps makes them more at risk to COVID-19. There is scarce information available on COVID-19 pregnancy and no reliable evidence for vertical transmission. It is a concern that newborns are risk from postpartum contamination. Meanwhile, there was no vaccine and specific therapeutic drugs for COVID19. The Multidisciplinary team will manage by close supervision, isolated negative pressure room, and routinely fetal monitoring. The timing and mode of delivery depend on the critical condition of the mother and fetal. The newborns need a14 days period of precautionary isolation. In the present study, addressed the most recent data on 149 pregnant women and 96 newborns with typical symptoms and planning of management which response to COVID-19 that will help for frontline doctor to the management of COVID-19 associated pregnancy and newborns baby. Repeated testing, contact tracing and self-isolation will assist to control the spread of SARS-CoV2 infection and COVID-19 disease until specific vaccine and pharmaceuticals drugs of COVID-19 are available.Entities:
Keywords: COVID-19; Neonate; Pregnant women
Mesh:
Year: 2021 PMID: 33966721 PMCID: PMC7983419 DOI: 10.1016/j.tjog.2021.03.005
Source DB: PubMed Journal: Taiwan J Obstet Gynecol ISSN: 1028-4559 Impact factor: 1.944
Fig. 1Structure of COVID-19.
Fig. 2Transmission pathways.
Clinical aspects and management of COVID-19 infected pregnant women.
| Authors | N = case | Age | Weeks of gestation | C/F | Progression | Treatment | Delivered | Neonatal outcomes | Neonatal complications |
|---|---|---|---|---|---|---|---|---|---|
| Chen et al. [ | 9 | 26–40 | 36–39 | Fever, malaise, cough | Pneumonia | Antiviral therapy | CS | Normal | No |
| Nan yu et al. [ | 7 | 29–34 | 37–41 | Fever, cough, fatigue | Pneumonia | Oseltamivir (75 mg 12 h, orally), Ganciclovir (0·25 g every 12 h, intravenously), interferon (40 μg daily) | CS | 1 had positive to SARS-CoV-2 | No |
| Huang hua leu et al. [ | 41 | 22–42 | 22–40 | Fever, cough, fatigue | Pneumonia | Antiviral therapy | Not reported | Normal | 3 had cough, fever, |
| Huaping Zhu et al. [ | 9 | 25–34 | 31–39 | Fever, cough, diarrhea | Pneumonia placenta previa | Oseltamivir, nebulized inhaled interferon | 2-VD | 1 died | No |
| Dehan Liu et al. [ | 15 | 23–40 | 12–38 | Fever, cough, sore throat, myalgia | Pneumonia | Antiviral therapy | 1-VD | Normal | No |
| Na Li et al. [ | 16 | 26–37 | 29–40 | Fever, cough, sore throat, dyspnea | Pneumonia | Antiviral therapy | 2 -VD | Normal | No |
| Xiaotong Wang et al. [ | 1 | 28 | 30 | Fever, cough | Fetal distress | Arbidol (0.2g administered orally every 8 h), | CS | Normal | No |
| Weiyong LIU et al. [ | 3 | 30–34 | 38–40 | Fever, cough | pneumonia | Atomized inhalation of interferon (40 μg, bid), Ganciclovir (0.25g, IV). | 1 -VD | Normal | 1had slightly decreased responsiveness and muscle tone |
| E. Kalafat et al. [ | 1 | 32 | 35 + 3 | Cough, dyspnea | pneumonia | Oseltamivir, Azithromycin, hydroxychloroquine | CS | Normal | No |
| Siyu Chen et al. [ | 5 | 25–31 | 38–41 | Cough, malaise, | Preeclampsia | Oseltamivir, azithromycin | 3 -VD | Normal | No |
| Fabio Parazzin et al. [ | 42 | 21–44 | 34–37 | Dyspnea, fever, cough | pneumonia | Not reported | 24-VD | Total 3 had Positivity to SARS-Cov-2, among 1 had missing information | 1had gastrointestinal and respiratory symptoms |
Abbreviations: CS = cesarean section, VD = vaginal delivery, GDM = Gestational diabetes mellitus.
Fig. 3Diagram of planning process for pregnant women with COVID-19 infection.